Fresh2 Group Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Fresh2 Group.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 23.2% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
AnPac Bio announces plan to implement ADS ratio change
Oct 18AnPac Bio-Medical Science announces management changes
Oct 03AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group
Sep 27AnPac Bio appoints Yuyang Cui as co-chief executive officer
Aug 05AnPac Bio stock soars 15% after securing first disease treatment patent in U.S.
Jun 18AnPac Bio wins new US patent for multi-cancer detection
Feb 01AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases
Dec 14Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%
Dec 11AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%
Nov 25AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%
Nov 02In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fresh2 Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2023 | 17 | -136 | -74 | -61 | N/A |
3/31/2023 | 11 | -110 | N/A | N/A | N/A |
12/31/2022 | 12 | -102 | -57 | -55 | N/A |
9/30/2022 | 11 | -61 | N/A | N/A | N/A |
6/30/2022 | 9 | -70 | -77 | -75 | N/A |
3/31/2022 | 18 | -104 | N/A | N/A | N/A |
12/31/2021 | 18 | -119 | -76 | -72 | N/A |
9/30/2021 | 25 | -98 | N/A | N/A | N/A |
6/30/2021 | 26 | -81 | -36 | -33 | N/A |
3/31/2021 | 22 | -88 | N/A | N/A | N/A |
12/31/2020 | 21 | -80 | -61 | -59 | N/A |
9/30/2020 | 12 | -112 | N/A | N/A | N/A |
6/30/2020 | 11 | -122 | -84 | -80 | N/A |
3/31/2020 | 10 | -105 | N/A | N/A | N/A |
12/31/2019 | 11 | -101 | -52 | -49 | N/A |
9/30/2019 | 12 | -69 | -38 | -41 | N/A |
12/31/2018 | 10 | -42 | -29 | -31 | N/A |
12/31/2017 | 6 | -39 | -24 | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if FRES's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if FRES's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if FRES's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if FRES's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if FRES's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FRES's Return on Equity is forecast to be high in 3 years time